novo oral glp-1 With FDA approval of Wegovy pill, new era of weight loss drugs begins Novo's Path To the First

Over the last decade, several studies have investigated the role of glucose-lowering drugs in cardiovascular outcomes, especially glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) which have demonstrated substantial improvements in major cardiovascular events, kidney function outcomes, and hospitalizations [3]

Note: Ozempic and Mounjaro are not FDA-approved to treat obesity or for weight loss

Instead, choose lighter preparation methods like grilling, steaming, or baking

Use of statins and risk of hospital admission for rhabdomyolysis

2026 might be the year that changes

Depression, antidepressants, and neurogenesis: a critical reappraisal